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This paper reports on the first 100 infants delivered con-
secutively the result of 63 pregnancies after conception in-
vitro at the Pacific In-Vitro Fertilization (IVF) Institute. These 
pregnancies were established prior to the introduction of 
embryo-cryopreservation into the program. Ninety-seven per-
cent (97%) of singleton pregnancies delivered after 36 weeks; 
only 5/31 (16%) required tocolytic therapy. The overall multi-
ple gestation rate was 51%, higher than in many other IVF 
centers. Maternal complications and neonatal morbidity were 
associated primarily with these multiple gestations. Forty-one 
percent (41%) delivered in < 36 weeks, and tocolytics were 
administered in 22127 (81%) of twin and 515 (100%) of triplet 
gestations. Neonatal morbidity was noted in 39 infants (33 
from multiple gestations); 28 neonates were admitted to the 
intensive care unit (27 from multiple gestations). Nine births 
had or developed minor abnormalities (hernias, pyloric steno-
sis). One case of Trisomy 21, and one infant death at 11 
months occurred in the group. The caesarean section rate for 
all IVF deliveries was 65%. It is concluded that IVF is clearly 
established in Hawaii for infertility refractory to other meth-
ods of treatment. The risk associated with IVF stem from the 
possibility of multiple gestations, not whether the pregnancy 
was initiated in-vitro. In the future, embryo cryopreservation 
may help to reduce the risk of multiple pregnancy. 
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Introduction 
Human In-Vitro Fertilization is now a well-accepted treat-
ment for infertility due to tubal blockage, endometriosis, male 
factor, immunologic and idiopathic causes'·2 • IVF has been 
offered in Hawaii since 1985 at the Pacific In-Vitro Fertiliza-
tion Institute at Kapiolani Medical Center for Women and 
Children, and most health insurers in the State will provide 
coverage for at least one complete treatment cycle. 
Since the first IVF birth in Hawaii in December 1985, 
more than 100 babies have been delivered (through July 
1990). The overall clinical pregnancy rate at the Institute is 
high, compared to other programs in the United States10, but 
an evaluation of the course of pregnancy and the delivery is 
also vital in evaluating the efficacy of this rapidly changing 
technology. This paper retrospectively summarizes data on the 
course of these first 100 IVF deliveries. 
Patients and methods 
Data on pregnancy, labor, and delivery and neonatal out-
come were obtained from the treatment charts on the first I 00 
sequential IVF babies born. The average maternal age was 34 
years (25-42 yrs). The mean duration of infertility was 6 
years. Forty-seven (75%) patients had never delivered a viable 
fetus prior to IVF and 23 (37%) had never become pregnant. 
Induction of ovulation was performed by controlled ovari-
an hyperstimulation with human menopausal gonadotropin 
(HMG), beginning either on cycle day 2 or following GnRH 
agonist (leuprolide acetate) suppression beginning on cycle 
day 21 4 • Oocytes were harvested either laparoscopically or, 
since November 1987, routinely while utilizing transvaginal 
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''It's the right decision for me 
and for my patients. '' 
HMSA offers health care providers like 
Dr. Hartman, a gastroenterologist in Honolulu, 
some very good reasons for joining our 
Participating Provider Program. Reasons like the 
competitive advantage he has with access to our 
more than 600,000 members- 90% of whom 
choose Participating Providers. Or the payments 
that he receives directly and promptly from 
you can depend on our staff to provide 
courteous and professional service. And your 
patients benefit by knowing in advance what 
their out-of-pocket costs will be. They feel secure 
that you and HMSA are working together to keep 
those costs under control. 
If you care about your patients' health care 
and its cost, being an HMSA Participating 
HMSA - that helps his cash 
flow and eases his 
administrative expenses. 
Provider makes sense. For H M SA more information on HMSA's 
Participating Provider 
Program, call 973-7700 on 
Oahu or your local HMSA office . 
Like Dr. Hartman, when 
you participate with HMSA, • 
'
Blue Cross 
Blue Shield 
• of Hawaii 
With you all the way. 
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ultrasonography, as an outpatient procedure. Oocytes were 
inseminated 4 to 20 hours after retrieval, and transfer of sever-
al of the embryos into the uterus was done typically at the 4-
cell stage, approximately 48 hours after egg retrieval. Subse-
quent, early, quantitative HCG tests and real-time ultrasound 
at 6 weeks confirmed clinical pregnancy. Prenatal care was 
then carried out by the patient's private obstetrician. 
TABLE 1 
Infants Delivered 
Singleton ..................................... 31 
Twin ............................................ 27 
Triplet ............................................ 5 
Male ............................................ 54 
Female ....................................... .46 
100 infants from 63 deliveries 
TABLE 2 
Causes of Infertility 
Tubal Factor ............................................... 31 (49%) 
Anovulation .................................................. 7 (11%) 
Endometriosis .............................................. 6 ( 1 0%) 
Male Factor ................................................... .4 (6%) 
Unexplained ................................................... 3 (5%) 
Multiple Factors (*) ..................................... 12 (19%) 
* including antisperm antibody in several patients 
Results 
Between December 1985 and July 1990, 100 infants were 
born in 63 deliveries (Table 1). Multiple gestations accounted 
for 32/63 (51%) of total pregnancies (27 twins and 5 triplets). 
The sex ratio was unremarkable (54 males, 46 females). The 
primary cause of infertility in this cohort had been a tubal fac-
tor; other less frequent causes included anovulation, 
endometriosis, male factor, immunological, and unexplained 
infertility (Table 2) . 
Most of the IVF pregnancies (78%) ended with delivery 
after 36 weeks (Table 3), including 97% of singletons and 
59% of the multiple gestations. Of the 14 births occurring pre-
maturely, eg <36 weeks, 13 were multiple. This comprised 
41% of all multiple gestations. In the case of twins and 
triplets, the average gestational ages were 35 and 31. 5 weeks 
respectively. These exhibited a wide range of gestational ages, 
twins: 21 to 39 wks; triplets: 23 to 36 wks. 
Maternal complications included preterm labor, gestational 
diabetes, active herpes infection, pregnancy-induced hyperten-
sion, and premature rupture of the membranes (Table 4) . The 
TABLE 3 
Duration of Gestation 
Weeks Total Singleton Multiple (*) 
(n=63) (n=31) (n=32) 
< 28 2 (3%) 0(0%) 2 (6%) 
28-31 5 (8%) 0 (0%) 5 (16%) 
32-35 7 (11%) 1 (3%) 6 (19%) 
> = 36 49 (78%) 30 (97%) 19 (59%) 
* mean gestational ages of 35 and 31.5 weeks for 
twins and triplets. 
TABLE 4 
Maternal Complications During Pregnancy 
Tocolytics required in 
Gestational Diabetes 
Pregnancy-Induced Hypertension 
Premature Rupture of Membranes 
Active Herpes Infection 
First Trimester Vaginal Bleeding 
Postpartum morbidity• 
Total 
(n=63) 
32 (51%) 
7 (8%) 
5 (8%) 
4 (6%) 
2 (3%) 
23 (37%) 
11 (19%) 
Singleton 
(n=31) 
5 (16%) 
2 (6%) 
0 (0%) 
0 (0%) 
2 (6%) 
ND 
ND 
Twins 
(n=27) 
22 (81%) 
4 (15%) 
4 (15%) 
3(11%) 
0 (0%) 
ND 
ND 
Triplets 
(n=5) 
5 (100%) 
1 (20%) 
1 (20%) 
1 (20%) 
0(0%) 
ND 
ND 
• includes maternal fever and use of antibiotics; anemia requiring transfusion; transient renal insufficiency. 
ND - not determined 
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latter two occurred only in the multiple pregnancy group. 
Only 5/31 (16%) of singletons required tocolytic therapy, 
compared to 22/27 (81%) in twins and 5/5 (100%) in triplets. 
Multiple gestation with abnormal presentation was a major 
reason for the overall caesarean section rate of 65% (Table 5). 
The caesarean rate for twins and triplets was 89% and 80%, 
respectively. 
Neonatal morbidity was documented in the case of 39 
infants that were born (Table 6). Twenty-eight neonates were 
admitted to the neonatal intensive care unit at Kapiolani Medi-
cal Center, almost all the result of multiple births. 
The reasons for extended hospitalization included severe 
prematurity, difficulty in feeding, respiratory problems, the 
need for antibiotics or hyperbilirubinemia. Two neonatal 
deaths occurred, one at 23 weeks in a triplet pregnancy and 
one at 24 weeks in a twin pregnancy. Additionally, 2 cases of 
intrauterine fetal demise took place, one at 21 weeks in a twin 
pregnancy, and one at 31 weeks in a triplet pregnancy associ-
ated with pregnancy-induced hypertension. Subsequently, one 
infant died at 11 months of age. 
A summary of developmental abnormalities appears in 
Table 7. Minor abnormalities were observed in 9 (9%) of 
infants. This included 7 hernias and 2 cases of pyloric steno-
sis. Seven out of the total occured in multiple gestations. One 
case of Trisomy 21 developed in a triplet pregnancy. 
Discussion 
Since the birth of the first IVF baby in 1978, human in-
vitro fertilization has become an ethically and medically 
·accepted treatment for infertility due to tubal disease, 
endometriosis, male factor, ovulatory dysfunction, immuno-
logical infertility and for unexplained causesl.2. Data presented 
here analyze retrospectively the outcomes in the first 100 IVF 
babies in Hawaii from the Pacific In-Vitro Fertilization Insti-
tute at Kapiolani Medical Center for Women and Children. 
The multiple pregnancy rate of 51% reported here is higher 
than the range of 12 to 35% reported in other programs5•9•11 • 
IVF clinical pregnancy rates upwards of 25% 2 only are 
achieved when several embryos are simultaneously trans-
ferred. Consequently, this increases the chances for multiple 
gestations5·.,7 which, in turn, are associated with a higher inci-
dence of maternal and fetal complications8 • The high rate of 
multiple gestations in our series is probably due to transferring 
an average of more than 3 embryos at a time. This strategy 
evolved in response to the one-time-only insurance benefit 
allowed by most insurers in the State of Hawaii, combined 
with the lack of embryo-cryopreservation at this stage of the 
program's development. 
At the Pacific IVF Institute, couples are counseled exten-
sively regarding the risks and options, and they participate 
actively in the choice of the number of embryos at transfer. 
Since January 1990, embryo cryopreservation has been 
offered at the Institute. This may significantly reduce the rate 
of multiple pregnancies. However, since worldwide experience 
has shown that a minimum of 3 embryos are required to opti-
mize even singleton pregnancy rates in fresh transfer cycles7, 
the risk of multiple pregnancy will probably continue until 
non-invasive methods of assessing embryo potential are devel-
oped. Until then, systematic identification of other factors pre-
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TABLE 5 
Indications for Caesarean Sections* 
Multiple gestation with abnormal presentation ..... 18 
Cephalopelvic disproportion ................................... 5 
Placenta previa ...................................................... .4 
Single pregnancy with abnormal presentation ........ 3 
Abruptio placentae .................................................. 2 
Active herpes infection ........................................... 2 
Fetal distress .......................................................... 2 
Chorioamnionitis ..................................................... 1 
Severe pregnancy-induced hypertension ............... 1 
Elective ................................................................... 3 
* number of cases. Total n = 41 (65% of cases) 
TABLE 6 
Neonatal Morbidity and Mortality 
Neonatal morbidity* ........................................ 39 (39%) 
Singletons ................................................... 6 (6%) 
Multiples .................................................. 33 (33%) 
Admission to neonatal intensive care unit.. .... 28 (29%) 
Singletons ................................................... 1 (1%) 
Multiples .................................................. 27 (27%) 
Neonatal mortality .............................................. 2 (0%) 
Infant mortality .................................................... 1 (1 %) 
* causes include severe prematurity, difficulty in 
feeding, respiratory problems, use of antibiotics 
and severe hyperbilirubinemia. 
**at 11 months of age. 
Minor: 
TABLE 7 
Infant Abnormalities 
hernia ...................................... 7 
pyloric stenosis ....................... 2 
Major: 
Trisomy 21 .............................. 1 
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• Rapid epigastric pain relief 1'2* 
• Fast and effective ulcer healing2'3'4 
PASSES THE ACID TEST 
*Most patients experience pain relief with the first dose. 
See adiacent page for references and brief summary 
of prescribing information. 
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AXID ® (nizatidine capsules) 
Brief S~mmary. Coosull file package insert fllr complete prescribing informatiOO. 
Indications and Usage: 1. Active duodenal ulcer-for up to 8 weeks of treatment. Most 
patients heal within 4 weeks. 
2. Maintenance llmpy- tor healed duodenal ulcer patients at a reduced dosage 
of 150 mg h.s. The consequences of therapy with Axid for longer than 1 year 
are not known. 
CootraiDdlcations: Known hypersensitivity to the drug. Because cross sensitivity m 
this class of compounds has been observed, H2-receptor antagonists, including Axid, 
should not be administered to patients with a histoty of hypersensitivity to other 
~-receptor antagonists. 
Precautions: General-1. Symptomatic response to nizalidine therapy does not 
preclude the presence of gastric matignancy. 
2. Dosage should be reduced to patients with moderate to severe renal insufficiency. 
3. In patients with normal renal function and uncomplicated hepatic dysfunction, 
the disposition of nizatidine is similar to that in norma! subjects. 
Laboratory Tests-False-positive tests for urobilinogen with Multistix11 may occur 
dunOQitlerapy. 
Drug Interactions-No interactions have been observed with theophylline, 
chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. Axid does not inhibit 
the cytochrome P-450 enzyme system; therefore, drug interactions mediated by 
inhibition of hepatic metabolism are not expected to occur. In patients given very 
high doses {3,900 mg) of aspirin daily, increased serum salicylate levels were seen 
when nizatidine, 150 mg b.i.d., was administered concurrently. 
Carcinogenesis, Mutagenesis, Impairment of Fertility-A 2-year oral wcinogenicity 
study in rats with doses as high as 500 mg/kg/day (about 80 times the recommended 
daily therapeutic dose) showed no evidence of a carcinogenic effect There was a 
dose-related increase in the density ofenterochromaffin-like (ECl)cellsin the gastriC 
oxyntic mucosa. In a 2-year study in mice, there was no evidence of a wcinogenic 
effect in male mice, although hyperplastic nodules of the liver were increased in the 
high-dose males as compared with placebo. Female mice given the high dose of Axid 
(2,000 mglkg/day, about 330 times the human dose) showed marginally statistically 
significant increases in hepatic carcinoma and hepatic nodular hyperplasia with no 
numerical increase seen in any of the other dose groups. The rate of hepatic carcinoma 
in the high-dose animals was within the historical control limits seen for the strain 
of mice used. The female mice were given a dose larger than the maximum tolerated 
dose, as indicated by excessive (30%) weight decrement as compared with concurrent 
controls and evidence of mild liver injury (transaminase elevations). The occurrence of 
a marginal finding at high dose only in animals given an excessive and somewhat 
hepatotoxicdose,wlthnoevidenceofacarcinogeniceffectinrats,malemice,andfemale 
mice (given up to 360 mg/kg/day, about 60 limes ~e human dose), and a negative 
mutagenicity battery are notconSideredevidenceolacarcinogenicpotentiallor Axid. 
Axid was not mutagenic in a battery of tests performed to evaluate its potential 
genetic toxicity, induding bacterial mutation tests, unscheduled DNA synthesis, sister 
chromatid exchange, mouse lymphoma assay, chromosome aberration tests, and a 
micronudeustest. 
In a 2-generation, perinatal and postnatal fertility study in rats, doses of nizatidine 
up to 650 mg/kg/day produced no adverse effects on the reproductive performance 
of parental animalsortheirprogeny. 
Pregnancy- Teratogenic Effects-Pregnancy Gategory C- Oral reproduction studies 
in rats at doses up to 300 times the human dose and in Dutch Belted rabbits at 
doses up to 55timesthehuman dose revealed noevidenceofJmpairedferti!ityor 
teratogenic effect; but, at a dose equivalent to 300 times the human dose, treated rabbits 
had abortions, decreased number of live fetuses, and depressed fetal weights. On 
intravenous administration to pregnant New Zealand White rabbits, mzatidine at 
20 mg/kg produced cardiac enlargement coarctation of the aortic arch, and cutaneous 
edema in 1 fetus, and at50mg/kg, itproducedventricularanomaly,distended 
abdomen, spina bifida, hydrocephaly, and enlarged heart in 1 fetus. There are, 
however, no adequate and well-controlled studies in pregnant women. It is also not 
known whether nizatidine can cause fetal harm when administered to a pregnant 
woman or can affect reproduction capacity. Nizatidine should be used during pregnancy 
only if the potential benefit justifies the potential risk to the fetus. 
Nursing Mothers-Studies in lactating women have shown that 0.1% of an oral 
dose is secreted in human milk in proportion to plasma concentrations. Because of 
growth depression m pups reared by treated lactating rats, a decision should be 
made whether to discootinue nursing or the drug, taking into account the importance 
ofthedrugtothemother. 
Pediatric Use-Safety and effectweness m children have not been established. 
Use in Elderly Patients-Healing rates 10 elderly patients were Similar to those 
in younger age groups as were the rates of adverse events and laboratory test 
abnormalities. Age alone may not be an important factor in the disposition of 
nizatidine. Elderly patients may have reduced renal function. 
Adverse Reactions: Clinical trials of varying durations included almost 5,000 patients. 
Among the more common adverse events m domestic placebo-controlled trials of 
over 1,900 nizatidine patients and over 1,300 on placebo, sweating (1% vs 0.2%), 
urticaria (0.5% vs <0.01%), and somnolence (2.4% vs 1.30Jo) were significantly 
more common with mzatidine. It was not possible to determine whether a variety of 
lesscommoneventswereduetothedrug. 
Hepatic-Hepatocellular injury (elevated liver enzyme tests or alkaline phosphatase) 
possibly or probably related to nizatidine occurred m some patients. In some cases, 
there was marked elevation (>500 lUll) in SGOT or SGPT and, in a single instance, 
SGPT was >2,000 lUll. The mcidence of elevated liver enzymes overall and 
elevations of up to 3 times the upper limit of norma!, however, did not significantly 
d!fferfromthatmplacebopatients.Ailabnormalitieswerereversibleafterdiscontlnuation 
of Axid. Since market introduction, hepatitis and jaundice have been reported. Rare 
cases of cholestatlc or mixed hepatocellular and cholestatic injury with jaundice 
have been reported with reversal of the abnormalities after discontinuation of Axid. 
Gardiovascular- !n clinical pharmacology studies, short episodes of asymptomatic 
ventricular tachycardia occurred in 2 individuals administered Axid and in 3 
untreated subjects. 
CNS-Rare cases of reversible mental confusiOn have been reported. 
Endocnne-Ciimcal pharmacology studies and controlled clinical trials showed no 
ewdence of antiandrogenic activity due to nizatldine. Impotence and decreased libido 
were reported with equal frequency by patients on nizatidine and those on placebo 
Gynecomastia has been reported rarely. 
Hematologic-Fatal thrombocytopenia was reported in a patient treated with 
mzatidme and another Hrreceptor antagonist This patient had previously expenenced 
thrombocytopenia whMe taking other drugs. Rare cases of thrombocytopenic purpura 
have been reported 
Integumental-Sweating and urt1caria were reported Significantly more frequently 
m mzatidine- than in placebo-treated patients. Rash and exfoliative dermatitis were 
also reported. 
Hypersensitwlty-As witt! other H2·receptor antagomsts, rare cases of anaphylaxiS 
followmg n12alldme admm1strahon have been reported. Rare epiSOdes of hypersensitiVIty 
reactrons [eg, broochospasm.laiYOQe3 edema, rash, and eoonopflilo) have lleen reported. 
Other-Hyperuricemia unassocialed with gout or nephrolithiasis was reported. 
Eosmophil!a, lever, and nausea related to mzatldme have been reported. 
OVerDosage: Overdoses of Axid have been reported rarely. If overdosage occurs, 
activated charcoal, emes1s, or lavage should be considered along w1th cflmca! 
momtoring and supportive therapy. Renal dialYSIS does not substantially mcrease 
clearance of mzatldme due to 1ts large volume of d1stnbul!on. 
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disposing to multiple IVF pregnancies, eg, maternal age, prior 
history of pregnancy, etc, may, in conjunction with cryopreser-
vation, help to reduce the risk of multiple pregnancy. 
Data indicate that multiple gestations account for the 
majority of maternal complications. The 22% pre-term deliv-
ery rate (<36 weeks) observed here is similar to that reported 
from other programs9·to.t2•13 • As expected, the rate was much 
higher for multiple gestations (41%) than for singletons (3%). 
However, older maternal age, in addition to multiple gestation, 
probably contributes to a high pre-tenn incidence of labor and 
delivery compared to primiparous patients who are not infer-
tile. The incidence of first trimester bleeding, pregnancy-
induced hypertension, premature rupture of membranes, and 
gestational diabetes is lower in our cohort than has been 
reported elsewhere10 • Our data support the conclusions by Bar-
low et al14 and Hill et al13 that such complications are no more 
prevalent than in other populations of patients with infertility 
treated by other means. However, the comparatively high use 
of tocolytics reported in our series (51% of cases) is most cer-
tainly due to the relatively higher rate of multiple gestations 
than has been reported in other centers. 
The higher multiple pregnancy rate also accounted for a 
high overall caesarean section rate (65%); 89% and 80% of 
twin and triplet pregnancies respectively, were delivered by 
caesarean section. Other authors have reported overall cae-
sarean section rates of 33 to 56% in IVF gestations9•11 •12• 
The overall incidence of neonatal morbidity (9%) is nearly 
identical to that reported by Yeh et aP 0 who reported an 8.6% 
incidence, including pyloric stenosis, bilateral inguinal hernias 
and tibial torsion. Hernias and pyloric stenosis occurred in our 
series. 
Summary 
There have now been more than 100 live births from in-
vitro fertilization performed at the Pacific In-Vitro Fertiliza-
tion Institute at Kapiolani Medical Center for Women and 
Children in Honolulu. Although our overall clinical pregnancy 
rates are comparable or better than those at other well-estab-
lished programs on the Mainland, multiple gestation remains 
one of the major challenges associated with higher rates of 
pregnancy. The rates and types of complications, however, are 
similar to those reported in other IVF centers and for other 
treatment modalities for infertility. Clearly, it is the presence 
of multiple gestations, and not whether the pregnancy was ini-
tiated in vitro, that should be viewed as the most important 
risk factor for complications in women with infertility who are 
treated by IVF13 • Advances in embryo-cryopreservation and 
the identification of risk factors may help to reduce the inci-
dence of multiples in the future. 
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warmers, to used anesthesia machines and OR tables. 
We expect that the interchange of ideas and techniques 
between the Chinese and the Hawaii volunteers will be mutu-
ally beneficial. We have undoubtedly as much to learn from 
them, as they do from us. The Mission promises to be an 
exciting opportunity to help others in need. 
The Board of Directors of this foundation consists of the 
following members: C. K. Yeo MD, Pon-sang Chan MD, 
Ming Chen MD, David Lee, Lester Leu Esq. Edward Ngan, 
Cheng-Hock Seah MD, George Shimomura MD, Ramon Sy 
MD, Brad Wong MD, Lockwood Young MD and Lisa A. 
Wong, Executive Administrator. 
• 
HAWAII MEDICAL JoURNAL-VOL. 50, No. 10-0croBER 1991 
